

Autoimmunity, autoantigens, autoantibodies

Edited by: K. Conrad (Dresden, Germany)

U. Sack (Leipzig, Germany)

Vol. 3 – 2002

*K. Conrad, M. Fritzler, M. Meurer, U. Sack,
Y. Shoenfeld (Eds.)*

From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies

Report on the 6th Dresden Symposium on Autoantibodies
held in Dresden on September 4-7, 2002



PABST SCIENCE PUBLISHERS
Lengerich, Berlin, Bremen, Miami,
Riga, Viernheim, Wien, Zagreb

Contents

Preface

K. Conrad, M. Fritzler, M. Meurer, U. Sack, Y. Shoenfeld 23

1. The impact of genomics/ribonomics/proteomics on autoantigen and autoantibody research

Using messenger RNP autoantibodies to reveal networks of posttranscriptional operons

J. Keene, S. A. Tenenbaum 26

Modern techniques in mass spectrometry based proteomics

M. Mann, J. Andersen, Y. Ishihama, J. Rappsilber, S. Ong, L. Foster, B. Blagoev, I. Kratchmarova, E. Lasonder..... 43

The use of phage display to identify a conformational autoepitope in primary biliary cirrhosis

M. Scealy, I.R. Mackay, M.J. Rowley 44

Anti-citrulline antibodies and citrullinating enzymes in RA

E. R. Vossenaar, T. Radstake, A. van der Heijden, P. Barrera, G. Pruijn, W. J. van Venrooij 45

A study of overlapping epitopes recognised by antibodies to GAD65 using phage display

K. H. O'Connor, M. Scealy, M. J. Rowley 46

Epitope-fine mapping of the major C-terminal epitope of the ribosomal P- proteins

M. Mahler, K. Kessenbrock, J. Raats, M. Blüthner 47

2. New diagnostic techniques in autoantigen/autoantibody analyses

New technologies in the detection of autoantibodies:

The present and future

M. Fritzler 50

Systematic analyses of microbial antigens and infection induced autoimmunity

P. Krebs, B. Ludewig, B. Metters, O. Türeci, R. M. Zinkernagel,

H. Hengartner, U. Sahin..... 64

Line-assay with recombinant antigens for diagnosis of systemic autoimmune rheumatic diseases

T. Kattenfeld, A. Kromminga, M. Motz..... 65

Three multiplexed tests for extractable nuclear antigens using the Luminex 100

R. W. Burlingame, A. L. Piette, C. von Mühlen, K. M. Pollard,

W. L. Binder 66

The BIOONE[®] system: the new dosage of autoantibodies

L. Voorn, P. Backelandt, A. Duyckaerts, L. Zecchinon, T. Swiatkowski,

A. Bosseloir..... 68

Automatized classification of HEp-2-cell based indirect immunofluorescence patterns by a novel computerized system

U. Sack, S. Knöchner, P. Perner, U. Pigla, M. Kamprad 70

Simple and sensitive detection of serum autoantibodies to full-length bullous pemphigoid antigen 180

E. Schmidt, A. Kromminga, D. Zillikens, U. Zimmermann 71

Rapid flow cytometric differentiation of anti-platelet antibodies with microspheres

M. Woetzel, S. Schroeder, U. Sack, F. Emmrich..... 81

3. Novel autoantibodies of diagnostic and / or pathogenic relevance

Novel cytoplasmic mRNP compartment recognized by human autoantibodies <i>E. K. L. Chan</i>	92
Autoimmune response to glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) is strongly associated with its cellular function in lupus patients <i>Y. Takasaki, K. Kaneda, H. Yamada, M. Nawata, K. Ikeda, M. Matsushita, R. Matsudairav, K. Takeuchi, N. Shindo, K. Murayama, H. Hashimoto</i>	93
Translational regulators as autoantigens in systemic autoimmune diseases <i>G. Steiner, K. Skriner, G. Fabini, E. Jimenez-Boj, N. Kedersha, C. Zimmermann, M. Tohidast-Akrad, G. Schett, R. Fritsch, E. Höfler, P. Anderson, J. Smolen</i>	116
Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations <i>H. van Eenennaam, J. H. P. Vogelzangs, L. Bisschops, L. C. J. te Boome, H. P. Seelig, M. Renz, D.-J. de Rooij, R. Brouwer, H. P. Pluk, W. J. van Venrooij, F. H. J. van den Hoogen, G. J. M. Pruijn</i>	122
Prevalence of Antibodies against Alpha-Fodrin in Sjögren ´s syndrome: Comparison of two Sets of Classification Criteria <i>T. Witte, T. Matthias, M. Oppermann, K. Helmke, H. H. Peter, R. E. Schmidt, M. Tishler</i>	124
New antibody pattern in liver transplant patients with genetic donor-recipient incompatibility for GSTT1 - Correlation with de novo-immune mediated hepatitis and monoclonal gammopathy <i>I. Wichmann, I. Aguilera, J. M. Sousa, A. Bernardos, E. Franco, J. R. García-Lozano, A. Núñez-Roldán</i>	126

Identification and molecular characterization of two autoantibody systems associated with the indirect immunofluorescence cytoplasm discrete speckled (IIF-CDS) pattern
C. C. F. C. Laurino, N. P. Silva, A. H. Straus, H. K. Takahashi, M. Benchimol, I. C. Almeida, R. Mortara, R. Tedesco, L. E. C. Andrade..... 128

NY-ESO1 autoantibody – a novel candidate for early diagnosis of lung cancer
K. Conrad, P. Krause, O. Türeci, W. Heine, U. Luxemburger, J. Mehlhorn, U. Sahin..... 130

Antibodies recognizing different retinal antigens are present in sera of patients with lung diseases
W. A. Gorczyca, R. Jankowska, I. Porebska, D. Witkowska, M. Kuropatwa 131

4. Induction of autoantibodies and autoimmune diseases

The pristane model of lupus
W. H. Reeves, H. B. Richards, A. Mizutani, H. Yoshida, D. Nacionales, M. Satoh 134

Infectious origin of antiphospholipid syndrome
Y. Shoenfeld, M. Blank..... 149

Oxidative modification of autoantigens
B. T. Kurien, K. Hensley, S. Ganick, M. Bachmann, R. H. Scofield..... 161

Epitopes and complementary epitopes of autoantigens:
Clinical and biologic significance
A. Tzioufas, J. G. Routsias, H. M. Moutsopoulos 180

Linear epitopes of two different autoantigens (La/SSB and myelin basic protein) with molecular similarity, produce different humoral responses
A. Terzoglou, J. G. Routsias, C. Sakarellos, M. Sakarellos-Daitsiotis, H. M. Moutsopoulos, A. G. Tzioufas 198

Induction of T cell dependent idiotypic / anti-idiotypic antibody response by complementary peptides from the immunodominant epitope 289-308 of the La/SSB autoantigen <i>M. G. Papamattheou, J. G. Routsias, E. E. Karagouni, C. Sakarellos, M. Sakarellos-Daitsiotis, H. M. Moutsopoulos, A. G. Tzioufas, E. N. Dotsika</i>	199
Rapid onset of intra- and inter-molecular epitope spreading by immunization with 4-hydroxy-2-nonenal modified 60 kDa-Ro <i>B. T. Kurien, S. Ganick, D. Obeso, M. McClain, Q. Pye, R. Schneider, R. H. Broyles, J. A. James, M. Bachmann, J. B. Harley, K. Hensley, R. H. Scofield</i>	200
Induction of autoantibodies in different mouse strains by the C-terminal peptide of SmD1 83-119 <i>G. Riemekasten, D. Langnickel, P. Enghard, A. Meine, F. Hiepe</i>	201
Apoptosis, a mechanism to break tolerance? <i>M. P. Bachmann, J. A. Gross, Z. Pan, A. D. Farris</i>	203
Apoptotic cleavage of the LEDGF/p75 autoantigen: Mechanism, impact on function, and possible role in the induction of autoantibodies <i>V. Ganapathy, X. Wu, T. Brown, T. Daniels, C. A. Casiano</i>	220
Mice transgenic for human La are tolerant to La antigen in the form of late apoptotic cells <i>Z. Pan, K. Davis, M. P. Bachmann, A. D. Farris</i>	247
Influence of Th1 and Th2 cytokines on the primary and secondary immune response in vitro <i>I. Sterzl, J. Votruba, P. Matucha, J. Sterzl</i>	248
Relationship between rheumatoid factors, immune complexes and galactosylation status of IgG during humoral immune response in hyperimmunized rabbits <i>D. Ciric, N. Milosevic-Jovic, V. Ilic, L. Hajdukovic-Dragojlovic</i>	250
Characteristics of the anti-dsDNA autoantibody response induced by Infliximab <i>P. Charles, L. Aarden, R. N. Maini</i>	251

Antinuclear antibody profile following infliximab treatment in rheumatoid arthritis and spondyloarthritis. <i>L. De Rycke, N. van Damme, E. Kruithof, I. E. A. Hoffman, F. van den Bosch, E. M. Veys, F. de Keyser</i>	252
Immune response to neo- or recall antigens is not altered by alefacept <i>A. Gottlieb, A. Vaishnav, K. Gordon</i>	254
Alefacept (human LFA-3/IgG1) is well tolerated and non-immunogenic: Results of two randomized, placebo-controlled phase III trials <i>G. Krueger, A. Vaishnav, K. Gordon</i>	256
Complexes of natural autoantibodies with histones perform role of novel autoantibodies <i>D. N. Abakushin, A. M. Poverenny</i>	258
The reactivity of human serum IgM antibodies with <i>Salmonella</i> outer membrane proteins as a potential marker of <i>Salmonella</i> carrier <i>A. Gamian, D. Witkowska, M. Staniszewska, W. Gorczyca, L. Maslowski</i>	260
Reactivity of antibodies against human muscle beta-enolase with bacterial outer membrane proteins <i>D. Witkowska, J. Pietkiewicz, B. Szostko, A. Gamian</i>	262
Increased blood plasma concentrations of TGF- β in patients with multiple sclerosis after treatment with IVIG <i>D. Reinhold, K. Schrecke, E. Perlov, H.-J. Heinze, M. Sailer</i>	264

5. Pathogenic effects of autoantibodies

Understanding the pathogenesis of ANCA: Where are we today? <i>E. Csernok</i>	266
Antibodies with catalytic activity <i>J. Bayry, S. Lacroix-Desmazes, D. Stahl, N. Misra, S. Delignat, V. Donkova, A. Pashov, M. D Kazatchkine, S. V. Kaveri</i>	280

GM1-specific antibodies trigger leukocyte inflammatory functions via IgG receptors <i>N. M. van Sorge, W.-L. van der Pol, P. A. van Doorn, J. van Strijp, J. G. J. van de Winkel, L. H. van den Berg</i>	288
Pathogenic effects of anti-retinal autoantibodies of autoimmune retinopathy <i>G. Ren, S. Shiraga, G. Adamus</i>	289
The effects of pathogenic antibodies to type II collagen on cartilage synthesis in vitro <i>S. F. Amirahmadi, M-P. van Damme, M. J. Rowley</i>	290
Evidence for immunity to type II collagen in the pathogenesis of rheumatoid arthritis: High frequency of antibodies to collagen fragment CB10 <i>M. J. Rowley, A. D. Cook, A. Stockman</i>	291
Binding properties of a sequence-specific pathogenic Lupus anti-ssDNA autoantibody <i>J. Cleary, J. Beckingham, R. Glick, G. D. Glick</i>	292
Molecular dissection of the Goodpasture epitope <i>T. Hellmark, K. Bolton, J. Wieslander</i>	294
The TNF-alpha induced upregulation of 52kD Ro/SSA autoantigen expression in human keratinocytes is mediated via TNF-alpha receptor I (TNF-RI) <i>B. Hostmann, V. Ruppert, M. Gerl, A. Waka, C. Johnen, F. Hiepe</i>	296

6. Pathogenic autoantibodies in pregnancy

Autoantibodies associated with reproductive failure <i>M. Blank, Y. Sherer, Y. Shoenfeld</i>	300
Pathogenesis of congenital heart block: Autoantibody insult to fibrosis <i>J. Buyon, R. M. Clancy</i>	314

Peptide display library to identify mimotopes of autoantigens associated with neonatal lupus
R. M. Clancy, F. Di Donato, E. K. L. Chan, J. P. Buyon.....328

7. Autoantibodies against receptor structures – Pathogenesis and therapy of anti-receptor-antibody induced diseases

The pathophysiological role of autoantibodies directed to G-protein coupled receptors and therapeutic strategies of antibody removal
G. Wallukat, E. Nissen, J. Müller, R. Brinckmann, I. Schimke, R. Kunze 332

Autoantibodies against the beta1-adrenoceptor increase L-type Ca^{2+} -current in human atrial myocytes
T. Christ, D. Dobrev, E. Wettwer, D. Müller, M. Knaut, G. Wallukat, U. Ravens 373

Translocation of the transcription factor NF-kappa B from cytoplasm into nucleus in cultured cells induced by TNF-alpha, and autoantibodies against alpha1-adrenergic and AT1 receptor
W. Schulze, V. Homuth, E. Nissen, D. Neichel, P. S. Leung, G. Wallukat..... 374

Functional monoclonal antibodies against the human beta1-adrenergic receptor
R. Mobini, A. Staudt, G. Wallukat, A. Mijares, J. Hoebeke..... 375

Induction of beta1-adrenergic receptor-directed autoimmune cardiomyopathy in the rat
R. Jahns, V. Boivin, S. Triebel, L. Hein, G. Ertl, C. E. Angermann, M. J. Lohse 376

The occurrence of autoantibodies against G-protein coupled receptors is associated with oxidative stress
I. Schimke 378

Specific removal of autoantibodies against beta1-adrenergic receptor from patients with dilated cardiomyopathy: Results from a pilot study
J. Müller 379

Agonistic antibodies targeting Angiotensin II type 1 receptor cause acute vascular rejection in the absence of immunological risk
D. Dragun, G. Wallukat, R. Dechend, J. H. Bräsen, D. N. Müller, H.-H. Neumayer, K. Budde, F. C. Luft..... 381

8. Autoantibodies in skin diseases

Pathogenic role of anti-Ro/SS-A autoantibodies in cutaneous manifestations of Lupus erythematosus
V. Ruppert, B. Hostmann, F. Hiepe 384

Anti-fibroblast autoantibodies in systemic sclerosis
P. L. Meroni, N. Ronda, E. Raschi, C. Testoni, M. O. Borghi, R. Gatti, J. M. Dayer, G. Orlandi, C. Chizzolini..... 396

Identity of the RNase MRP and RNase P associated Th/To-autoantigen
H. van Eenennaam, J. H. P. Vogelzangs, D. Lugtenberg, F. H. J. van den Hoogen, W. J. van Venrooij, G. J. M. Pruijn..... 417

Autoantibody populations directed against different transglutaminase isoenzymes in dermatitis herpetiformis and coeliac disease
M. Sárdy, S. Kárpati, B. Merkl, M. Paulsson, N. Smyth 418

Molecular pathomechanisms of autoimmune subepidermal bullous skin diseases
A. Kromminga, D. Zillikens 431

A Highly Sensitive and Simple Assay for the Detection of Circulating Autoantibodies against Full-Length Bullous Pemphigoid Antigen 180
E. Schmidt, A. Kromminga, S. Mimietz, U. Leinfelder, E.-B. Bröcker, D. Zillikens, U. Zimmermann..... 449

Anti-stratum corneum antibodies in active psoriasis
M. Cojocar, S. Popescu, A. Cimpean, D. Iordachescu, M. Costache 451

9. Autoantibodies against citrullinated antigens

Anti-CCP antibodies in (early) rheumatoid arthritis
E. R. Vossenaar, W. J. van Venrooij, G. J. M. Pruijn..... 454

“Citrullinated” antigens as targets of rheumatoid arthritis specific autoimmune responses <i>S. Chapuy-Regaud, M. Sebbag, L. Nogueira, C. Vincent, G. Serre</i>	463
Anti-citrullinated peptides autoantibodies or anti-filaggrin autoantibodies: What is the best for diagnosis of RA? <i>C. Ferraro-Peyret, J. Tebib, S. Veber, N. Fabien</i>	469
Detection of anti-CCP and diagnosis of rheumatoid arthritis <i>R. W. Burlingame, R. Morris, A. Metzger, C. von Muhlen, M. H. Wener, C. L. Peebles, A. L. Piette</i>	470
Comparison of anti-CCP (cyclic citrullinated peptide) assays in rheumatoid arthritis <i>A. Mustila, A. M. Haapala</i>	471
Comparison of several laboratory tests used in diagnostics of rheumatic diseases <i>I. Lochman, V. Novák, A. Kloudová, A. Lochmanová</i>	473
Antibodies to cyclic citrullinated peptide in RA: A sensitive and specific diagnostic marker <i>P. J. Charles, R. N. Maini</i>	474
The diagnostic significance of autoantibodies in patients with very early rheumatoid arthritis <i>V. P. K. Nell, K. P. Machold, W. Hueber, G. Eberl, H. Hiesberger, E. Hoefler, J. S. Smolen, G. Steiner</i>	476
Anti-keratin and anti-cyclic citrullinated peptide autoantibodies in patients with juvenile idiopathic arthritis <i>I. Hromadnikova, K. Stechova, P. Vavrincova, D. Hridelova, H. Nekvasilova, H. Reitzova, J. Vavrinec</i>	478
Juvenile idiopathic arthritis and anti-keratin/anti-CCP antibodies <i>K. Conrad, J. Oppermann, D. Möbius, M. Borte, G. Heubner</i>	480

10. Autoantibodies in thrombotic diseases and atherosclerosis

- Anti-prothrombin antibodies: Pathogenesis and specificity
T. Koike, T. Horita, K. Ichikawa, O. Amengual, T. Atsumi 482
- Antibodies against β_2 glycoprotein 1 and cardiolipin in rheumatoid arthritis patients with cardiovascular diseases
A. Durazinska, M. Szmyrka, B. Jazwiec, J. Szechinski..... 490
- Relationship between autoantibodies against oxidized LDL, lipid peroxidation products and cytokine profile in diabetic type 2 patients
H. Donica, M. Koziol-Montewka, E. Staroslawska 492
- Antineutrophil cytoplasmic antibodies in patients with Buerger's disease
I. M. Manolova, D. P. Petkov, M. Gulubova..... 493
- Anti-cholesterol antibodies in atherosclerosis
A. Horvath, G. Füst, P. Antal-Szalmás, I. Csipö, S. Sipka, I. Karádi..... 494
- Anti beta-2 glycoprotein 1 antibodies and 17 beta-estradiol serum levels in female rheumatoid arthritis patients
R. Sokolik, A. Durazinska, M. Szmyrka, J. Szechinski 495
- Evaluation of a renewed cardiolipin antibody assay - requirements of GMP confirm production
W. Papisch, T. Frey, B. Berg 496

11. Autoantibodies in liver and gastrointestinal diseases

- The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease
T. Freitag, G. Melino, H. Schulze-Koops, G. Niedobitek, E. G. Hahn, D. Schuppan 498
- Biological functions of coeliac disease autoantibodies
T. Halttunen, R. Marzari, D. Sblattero, M. Mäki 502

Anti-tissue transglutaminase antibodies: Prevalence and clinical significance in connective tissue diseases and autoimmune gastro-intestinal diseases <i>N. Bizzaro, D. Villalta, E. Tonutti, A. Doria, M. Tampoia, D. Bassetti, R. Tozzoli</i>	503
Assay of coeliac disease autoantibodies applying an ELISA with human tissue transglutaminase <i>A. A. Osman, T. Richter, M. Stern, K. Conrad, J. Henker, C. Brandsch, K.-P. Zimmer, T. Mothes</i>	506
Reactivity of mouse gliadin antibodies with deamidated gliadin <i>F. Kahlenberg, I. Lachmann, S. Tschiedel, J. Schneider-Mergener, A. A. Osman, U. Sack, T. Mothes</i>	507
Prevalence of pancreatic autoantibodies in patients with inflammatory bowel disease (IBD), their first-degree relatives and spouses <i>S. Joossens, L. Godefroidis, G. Claessens, S. Vermeire, M. Pierik, N. Esters, R. Aerts, X. Bossuyt, P. Rutgeerts</i>	511
ANCA and inflammatory bowel disease: Antigenic specificity <i>E. Mainardi, L. Cresci, M. T. Romagnoli, A. Vagni, P. Galli, A. Montanelli</i>	512
ANCA target antigen(s) in patients with autoimmune hepatitis <i>A. Kozmar, R. Ostojic, Z. Krznaric, B. Vucelic, B. Malenica</i>	514
Prevalence of anti-UDP-glucuronosyltransferase autoantibodies in patients with autoimmune hepatitis. <i>A. Desbos, J. Magdalou, E. Benoit, F. Lopicque, J. C. Monier, S. Veber, N. Fabien</i>	515
Detection of antiphospholipid-antibodies in patients with primary biliary cirrhosis and autoimmune hepatitis <i>P. von Landenberg, R. Schlichting, J. Schölmerich, G. Lock</i>	516
The frequency and pattern of autoantibodies and immunoglobulin levels in chronic hepatitis <i>A. Pituch-Noworolska, A. Macura-Biegun</i>	518

Prevalence of various autoantibodies in patients infected with hepatitis C virus <i>V. Tabor, M. Fucek, I. Hrstic, Z. Krznaric, B. Vucelic, B. Malenica</i>	520
Laboratory findings in autoimmune liver diseases patients in the Sverdlovsk region, Russia <i>V. V. Bazarny, E. N. Bessonova, D. A. Mazein, O. M. Lesnyak</i>	521

12. Autoantibodies in neurological and endocrine diseases

Autoimmune disorders of the neuromuscular junction <i>B. Lang, A. Vincent</i>	524
Diversity of neurological disorders with anti-GAD antibodies <i>J. Honnorat</i>	542
Paraneoplastic neuropathies – Clinical and immunological features <i>F. Blaes, M. Klotz, M. Tschernatsch, J. Kraus, I. Krasenbrink, M. Kaps</i>	553
Clinical outcome of paraneoplastic cerebellar degeneration associated with antineuronal antibodies in 48 patients <i>S. Shams-Ili, J. Grefkens, B. de Leeuw, H. Hooijkaas, P. Sillevs Smitt</i>	558
Autoantibodies in children and adults with paraneoplastic Opsoclonus-myoclonus syndrome <i>V. Fühlhuber, I. Krasenbrink, I. Juhasz-Böss, M. Klotz, M. Kaps, F. Blaes</i>	560
EUROLINE-WB allows reliable differentiation of autoantibodies against neuralantigens in patients with paraneoplastic neurological syndrome <i>T. Scheper, M. Klotz, W. Meyer, W. Schlumberger, W. Stöcker</i>	562
Autoantibodies to gangliosides in patients with multiple sclerosis and normal healthy controls <i>C. Wehrend, U. Sack, F. Emmrich, M. Kamrad</i>	564
Analytical and clinical evaluation of second generation assays for thyrotropin receptor antibodies. <i>D. Villalta, R. Tozzoli, E. Orunesu, P. Montagna, G. Pesce, N. Bizzaro, M. Bagnasco</i>	566

Cytofluorimetric evaluation of antigen regions of thyroid peroxidase in patients with Graves' disease and non-toxic nodular goiter <i>A. Bossowski, A. Stasiak-Barmuta, B. Czarnocka, M. Urban, J. Dadan</i>	568
Reactivity of anti-liver-kidney microsome type 1 (LKM-1) antibodies in the sera of patients with type 1 diabetes mellitus <i>O. Neacsu, M. Cojocaru, I. Cojocaru, D. Cheta</i>	570
Study of anti-actin and anti-myosin antibodies in myasthenia gravis <i>I. Cojocaru, M. Cojocaru, R. Tanasescu, C. Musuroi</i>	571
Autoantibodies in Hashimoto's encephalitis <i>J. Abu-Isa, M. Bodemer, S. Poser, A. Schlüter, I. Zerr</i>	572
HLA association with autoimmune endocrinopathies <i>P. Hrdá, F. Koriath, P. Matucha, I. Sterzl, A. Kromminga</i>	573
Prevalence of antitransglutaminase antibodies in a pediatric population with type 1 diabetes. <i>F. Bienvenu, N. Peretti, A. Lachaux, M. Nicolino, G. Tanzilli, C. Bouvet, R. Bouvier, S. Veber, J. Bienvenu, N. Fabien</i>	575
Multiple and high-titer single autoantibodies in schoolchildren reflecting the genetic predisposition for type 1 diabetes <i>M. Schlosser, R. Wassmuth, M. Strebelow, I. Rjasanowski, B. Ziegler, M. Ziegler</i>	577
Autoantibody profile in acute inner ear diseases <i>M. Kamprad, K. Donaubauer, K. Conrad, B. Kniep, U. Fickweiler, H. Müller, U. Sack</i>	579

13. Autoantibodies and epidemiology

The epidemiology of autoimmune diseases: Contribution of previous studies and opportunities for future research <i>G. Cooper</i>	582
The role of exogenous factors in the induction of autoantibodies <i>K. Geisenhoffer, D. Germolec</i>	604

Iodine prophylaxis and risk of arising autoimmune thyroid diseases in children
V. Aranovich, M. Svinarev..... 616

Autoantibodies in risk groups for autoimmune diseases
K. Conrad, J. Mehlhorn..... 617

14. Methodical aspects and diagnostic strategies

ANA

Clinical and laboratory evaluation of an ELISA, indirect immunofluorescence and a new automated fluorescence immunoassay for detection on antinuclear antibodies
A.-M. Haapala, A. Mustila, M. Pertovaara 620

Comparison of screening by IIF (HEp 2) and an ANA ELISA vs a new automated ANA/ENA screening (EliA) in patients from routine
M. I. Casas, F. Cava, F. J. Fernandez, S. Valor, J. M. Gonzalez-Buitrago, C. Gonzalez, B. Garcia, J. A. Navajo, W. Papisch 622

Comparison of screening by IIF (HEp 2) vs a new automated ANA/ENA screening (EliA) in defined patients
C. Gonzalez, J. M. Buitrago, M. Casas, F. Cava, B. Garcia, J. A. Navajo, W. Papisch, S. Valor 624

Pattern of humoral autoimmunity in patients with breast cancer
M. Volkmann, Y. Hajjar, J. Huober, D. Gaugel, J. Ludwig, S. Hänsel, G. Bastert, H. Zentgraf, D. Wallwiener, W. Fiehn 626

Nucleosome and dsDNA antibodies

A comparative study of the diagnostic efficiency of anti-dsDNA antibody tests in systemic lupus erythematosus
B. Schlüter, L. Kaucikaite, H. Schotte, P. Willeke, H. Becker, A. Dyong, J. Haier, R. Gellner, G. Bonsmann, M. Gaubitz..... 628

Clinical evaluation of a new dsDNA-RIA
R. Wöhrle, P. von Landenberg, M. Oppermann, K. Helmke, T. Witte 630

Detection of dsDNA antibodies in SLE: Efficiency of the automated EliA-immunoassay in comparison with non-automated systems <i>D. Kuhn, S. Kadler, E. Boehme, M. Linnemann</i>	632
Performance of a new automated fluorescence immunoassay (EliATM dsDNA) for the follow-up of anti-ds DNA antibodies in SLE patients <i>A. Lakaf, C. Sapin, V. Moal, J. R. Harlé, M. Sanmarco</i>	634
Detection of dsDNA antibodies in SLE: A case report based evaluation of discrepant results between the automated EliA immunoassay and an established non-automated assay <i>D. Kuhn, S. Kadler, E. Boehme, M. Linnemann</i>	635
Comparison of two different methods for detection of dsDNA antibodies related to SLE patients at different disease status <i>M. Rodriguez-Mahou, F. J. López-Longo, J. L. Ruiz-Tiscar, E. F. dez-Cruz</i>	637
Autoantibodies against nucleosomes are pathognomonic for SLE – A 2nd generation ELISA shows no reactivity with sera from scleroderma patients <i>W. Schlumberger, C. Daehnrich, W. Suer, S. Frahm, W. Stoecker</i>	639
The benefit of anti-deoxyribonucleoprotein (anti-DNP) antibodies determination in the laboratory of clinical immunology <i>I. Lochman, L. Cebecauer, V. Novák, H. Tomácková, A. Kloudová, A. Lochmanová</i>	641

ENA antibodies

Evaluation of the detection of anti-dsDNA and -ENA antibodies by a new automated fluorescence immunoassay <i>M. López-Hoyos, H. López-Escribano, M. Peña, M. J. Bartolomé</i>	643
Evaluation of EliA TM screening and detection of antibodies directed against extractable nuclear antigens <i>E. Oris, C. Bunn, G. Godefridis, N. Kolbus, W. Papisch, X. Bossuyt</i>	645

A new fluorescence immunoassay (EliA™ Sm) for the detection of anti-Sm antibodies <i>M. Mahler, R. C. Williams</i>	647
A new LINE immunoassay for the detection of myositis-specific autoantibodies <i>C. Hentschel, J. Schulte-Pelkum, W. Schöblier, F. Hiepe, R. Mierau, K. Conrad</i>	649
Antibodies against SS-A can only be precisely detected using the native antigen: Results of a study using the EUROLINE-WB <i>W. Meyer, T. Scheper, K. Wilhelm, M. Jarzabek-Chorzelska, Z. Kolacinska-Strasz, W. Schlumberger, W. Stoecker</i>	651
ANCA and GBM antibodies	
Increased specificity for systemic vasculitis with capture ELISA for MPO-ANCA? <i>M. Carlsson, J. Wieslander, M. Segelmark</i>	653
Evaluation of a new sensitive ELISA for the detection of PR3 Antibodies <i>M. Mahler, P. Höpfl, E. Mummert</i>	654
Antineutrophil cytoplasmic antibodies in connective tissue diseases <i>G. Kirdaite, J. Dadonien, E. Redaitiene</i>	655
Serum anti-glomerular basement membrane antibodies in patients with renalpulmonary syndrome <i>D. Iordanescu, M. Cojocar, I. Cojocar, O. Neacsu</i>	657
Colour pictures	659
Index of authors	677
Subject index.....	686

Preface

Autoimmune phenomena are a central pathogenetic principle involved in induction, progression and perpetuation of a broad range of diseases. Systemic autoimmune diseases are chronic, often not curable and have an important impact on the life quality of patients. Despite all progress in immunological research, etiology of most autoimmune diseases still remains unclear. Beside systemic autoimmune diseases, organ-specific and vascular diseases as well as tumors are associated with a variety of immunopathological phenomena. Much has been done in the last years to improve diagnosis and patients' treatment in the field of autoimmune diseases. This book reflects the progress in understanding of associations between diseases and autoantibodies from proteomics to molecular epidemiology. The impact of genomics, ribonomics and proteomics on autoantigen and autoantibody research is presented by new findings based on investigating messenger RNP autoantibodies and applications of mass spectrometry and phage display techniques. Conformational autoepitopes in primary biliary cirrhosis, anti-citrulline antibodies in rheumatoid arthritis, GAD65 epitopes and C-terminal epitopes of ribosomal P-proteins represent some improvement in the repertoire of autoantibodies. Novel autoantibodies against cytoplasmic mRNP, glyceraldehyde-3-phosphatase dehydrogenase, translational regulators, small nucleolar ribonucleoprotein complexes and yet unidentified antibody patterns promise improvement in diagnosis of autoimmune diseases, cancer, hepatitis and other diseases. Despite their correlation with diseases, the induction of autoantibodies remains a field of further research. Animal models, investigation of antibody induction by infectious agents, immunization, antigens with molecular similarity, epitope spreading and apoptotic processes and biological therapeutics such as monoclonal antibodies promise fascinating new insights into pathogenetic processes. Pathogenic effects of autoantibodies are illustrated by pathogenetic investigations on ANCA, catalytic antibodies, autoantibodies against gangliosides, receptors, retinal antigens, type II collagen or epitopes in Goodpasture syndrome. New developments and challenges in the field of diagnostic serology have rapidly become apparent. Beside methodological approaches such as systematic analysis of microbial antigens and infection

induced autoimmunity, novel technical solutions for routine diagnostics such as immunofluorescence with transfected cell substrates, multiplexed bead array tests, "LINE" assays, or autoantigen/peptide arrays improve the possibilities of patients' care and clinical research.

The editors

K. Conrad

M. Fritzler

M. Meurer

U. Sack

Y. Shoenfeld

2.

New diagnostic techniques in autoantigen/
autoantibody analyses

New technologies in the detection of autoantibodies

M. J. Fritzler

Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

Introduction

Autoantibodies to intra-cellular antigens are a diagnostic hallmark of autoimmune diseases that include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SjS), rheumatoid arthritis (RA), polymyositis (PM), organ specific autoimmune conditions, and paraneoplastic syndromes. Historically, autoantibody detection and analysis has relied on a number of different technologies such as particle aggregation, immunodiffusion (ID), indirect immunofluorescence (IIF), complement fixation (CF), hemagglutination (HA), counterimmunoelectrophoresis (CIE), radioimmunoassay (RIA), western and dot immunoblotting (IB), ELISA and functional assays that demonstrate inhibition of the catalytic or other functional activity of the antigen. These conventional technologies have limitations because they tend to be labor-intensive, time consuming, limited in throughput, semi-quantitative, and are not adaptable to leading-edge research.

ID has been used in clinical laboratories for over fifty years because it is inexpensive and the results are specific. However, ID lacks sensitivity and can take up to 48 hours before precipitin lines are interpretable (Figure 1). CF can detect antibodies that are relevant to pathogenesis but it is a laborious technique and less sensitive because not all autoantibodies fix complement. RIA is a sensitive technique but requires specialized equipment and facilities to handle and dispose of radioisotopes. IB is sensitive and allows precise identification of autoantibody targets in crude or purified tissue preparations, but it is costly, time consuming and not all autoantibodies are detected by this technique. IP protocols that use extracts from radiolabeled cells are not suitable




Fig. 1: Tools of the trade for autoantibody testing still in use today date back fifty years. Double (Ouchterlony) immunodiffusion utilized agarose gels and a well cutter (panel a). An antigen source, such as extracts of acetone powdered rabbit thymus (RTE) or other cell extracts, were placed in the center well and in the flanking wells control and test sera were placed. After incubation for 12-48 hours precipitin lines were visible and the identity of the autoantibody based on lines of identity, such as illustrated by the adjacent anti-RNP sera (panel b). By comparison, sera with anti-Sm, -PCNA and -SS-B/La did not produce lines of identity.

for the detection of all autoantibodies, although in some specialized cases IP remains the assay of choice. For example, in the SS-A/Ro system it has been observed that IP techniques are required to identify sera that contain antibodies reacting only with the 52 kDa antigen (1) or the 'native' SS-A/Ro particle (2;3). ELISA techniques have rapidly advanced, but highly specific, sensitive and reliable assays that use highly purified or recombinant proteins are expensive and limited by inter-manufacturer and inter-laboratory variation of

results (4;5). Some laboratories continue to use CIE for the detection of certain autoantibodies such as SS-A/Ro (6;7), although this technique generally favors high titer sera and often cannot discriminate multiple autoantibody responses that are characteristic of systemic rheumatic disease sera.

Despite the advantages of IP, CIE and ELISA, IIF that utilizes HEp-2 and other cell substrates remains the least expensive technique to perform. Autoantibodies are notably heterogeneous with respect to antigen specificity and polyclonality of the B cell response that leads to their formation. These factors, combined with antibody avidity and expression of IgG subclasses, can account for considerable differences in inter-laboratory sensitivity and specificity of test results. The use of IIF to detect antibodies can be limited by a lack of specificity and sensitivity when the antigen in question is of low abundance (8) or there is diffusion of the antigen from the cells during fixation (9). These factors have resulted in significant lot to lot variation from the same manufacturer. Another limitation of current IIF substrates is that there are significant differences in the sensitivity of different commercially available substrate kits to detect different antibodies.

Compared to ELISA and newer technologies, IIF lacks sensitivity and the ability to distinguish autoantibodies to specific molecular targets (10). On the other hand, an advantage of IIF over homogeneous assays such as ELISA, is the ability to simultaneously detect autoantibodies in a single serum. For example, sera from primary biliary cirrhosis typically have anti-mitochondria antibodies but may also contain autoantibodies that react with other relevant antigens such as nuclear pore complexes and centromere proteins (CENPs) that may have additional diagnostic and prognostic importance.

Newer test systems and assays include cells transfected with cDNAs of antigens of interest, "LINE" assays, solid-phase antigen arrays and laser bead arrays where relevant native or recombinant antigens are bound to a solid phase matrix. These new advances are only the beginning of what is becoming a rapid succession of more novel technologies such as microfluidics and nanotechnology. An obvious goal for these technologies is to enhance reliability, sensitivity and cost-effectiveness. Historical analyses suggest that any gains in accuracy obtained with new technologies may be clouded by a need to re-evaluate current paradigms of the diagnostic and prognostic specificity of autoantibodies.

Transfected cell substrates

On most commercial HEp-2 cell preparations, human anti-SS-A/Ro antibodies give a fine speckled nuclear staining pattern (1;9). Although this staining pat-

tern on untransfected cells is quite distinctive, other autoantibodies can produce similar patterns of staining and the presence of other autoantibodies can mask the SS-A/Ro staining pattern. One approach to the problem of sensitivity and specificity of the SS-A/Ro system is the technique of transfection where the appropriate gene(s) (i.e. 60 kD SS-A/Ro gene) are inserted into mammalian cells. This technique introduces multiple copies of the gene, which under the control of specific promoter-regulator genes (11) leads to “over-expression” of the gene of interest. This approach has been utilized in the manufacture of an IIF kit which utilizes the widely used HEP-2 cells transfected with a 60 kD SS-A/Ro cDNA (12). The staining pattern on transfected and overproducing cells is uniquely found in only a portion of the cells in a single high powered field (Figure 2). This feature is helpful because it permits identification of staining by other autoantibodies in the same field of view as the characteristic staining pattern of SS-A/Ro on transfected cells. The variation in 60 kDa SS-A/Ro expression is due to a number of factors including the cell cycle and regulation of expression of the promoter adjacent to the transfected gene (12).




Fig. 2: Indirect immunofluorescence of human sera containing antibodies to the 60 kD SS-A/Ro antigen on HEP-2 cells that were transfected and over-expressing the respective antigen. The identification of a positive reaction is characterized by intense nuclear staining of approximately 25% of the cells (arrows). The staining pattern was typically strongest in nucleus (speckled) and nucleolus, and weaker cytoplasmic staining can also be seen. Original magnification x400.

HEp-2 cells transfected with a 60 kDa human cDNA have been shown to be sensitive and specific substrates for the detection of SS-A/Ro antibodies (13-19). The development of a HEp-2 substrate that detects SS-A/Ro autoantibodies has several advantages. First, a substrate which can be used to screen sera for the presence of a wide variety of nuclear and cytoplasmic antibodies, has the added benefit of being able to detect SS-A/Ro antibodies as well. If the product is competitively priced, the ability to detect SS-A/Ro antibodies with a single test should result in savings for the clinical laboratory and the health care system. Second, because SS-A/Ro antibodies can now be detected by IIF, the turnaround time of reporting could be decreased. Third, the use of the transfected HEp-2 substrate can be adapted to a variety of clinical laboratory settings. For example, laboratories that are not equipped to test samples by IIF can use this substrate in an immunoenzyme assay (20). Fourth, two or three assays are typically required to reliably detect SS-A/Ro antibodies in human sera. The use of this substrate could replace the use of expensive (ELISA, IB) and toxic reagents (radioisotopes) to detect SS-A/Ro antibodies in the clinical laboratory. It has been shown that HEp-2 cells transfected with SS-A/Ro are more sensitive than ELISAs that use recombinant proteins (12).

Transfection techniques can also be used for other autoantibody systems. For example, we have used this technique to transfect HEp-2 cells with the paraneoplastic Hu-D and Yo cDNAs (unpublished) and then used these substrates as alternatives to cryopreserved cerebellum sections for the detection of respective autoantibodies.

Line assays

The ability to produce large amounts of purified and recombinant autoantigens has provided an important advantage to the development of new diagnostic technologies. Included in these newer assays are so-called "LINE assays". LINE assays are based on a solid phase matrix such as a nylon membrane or other protein-binding media on plastic backed sheets. Individual recombinant or highly purified antigens are applied as thin lines, the sheets cut into narrow strips of 0.2 – 0.5 cm, and then each strip is used in an identical manner as conventional IB (Figure 3). A control line is included at the top of each strip to allow for alignment and a template that identifies reactive bands is provided to assist with the visual interpretation of the positive results. In some kits, a "cutoff" strip is also provided that permits distinguishing positive from negative reactivity. Commercial kits based on this technology are marketed by Innogenetics (INNO-LIA ANA™, Ghent, Belgium; in North America, Innogenetics Inc., Norcross, GA, USA); Diagnostic Products Corpo-




Fig. 3: Analysis of human autoantibodies by IB using a line assay (InnoLIA). A typical analysis of human sera incubated with individual test strips (top panel) is shown. Strips are aligned with the aid of a marker at the top of a strip and reactive antigens on individual bands are identified with the aid of a reference strip (left hand lane). The identification of a reaction as positive or negative is based on the intensity of the band that must be stronger than the 'background' strip (lane 1). Results are indicated on a check-off sheet (bottom panel) and the results can be archived in a standard three ring binder.

ration (ANA LINE Blot, Los Angeles, CA, USA), and by SLR Research (ENA ImmuStrip™, Carlsbad, CA, USA).

Some of these assays have been validated in multicenter evaluations and, for the most part, have been shown to be a reliable alternative to ELISA and western immunoblotting (21). The advantages are a rather impressive in that up to 20 of the more common autoantigens can be assayed in a single test. Unlike conventional immunoblotting where total or soluble cell proteins are blotted onto a membrane, the separation of these antigens into clearly demarcated lines permits rapid identification of those antigens that are reactive with individual sera (Figure 3). The ability to rapidly determine multiple reactivities in a single serum sample has obvious advantages over a homogeneous ELISA or time-consuming immunodiffusion assays (22). Some of the shortcomings of LINE assays are difficulties in adapting the technology to a high volume laboratory, although an automated immunoblotting apparatus is available. In addition, borderline results are often difficult to interpret as positive or negative. Densitometry of the reactive bands might be helpful, but this adds another rather time- and labor-intensive step to the process.

A useful application of LINE assays is to analyze “difficult” sera. For example, from time to time the clinical laboratory encounters sera that appear to have multiple reactivities (i.e. Sm + U1-RNP + SS-A) or the presence of autoantibodies that might otherwise be unanticipated based on publications. These sera are very difficult to analyze using immunodiffusion or counterimmunoelectrophoresis and multiple ELISA assays are required to sort out the autoantibody complexity. In addition, in some instances the autoantibody result may not be in agreement with clear clinical findings (i.e. ANA-negative SLE, SjS, SSs). In this setting LINE assays have provided useful insight into the presence of autoantibodies that might not be anticipated (23) or detected by other assays (13).

Autoantigen arrays

Microchip/membrane spotted arrays

The autoantigen microarray fundamentally uses equipment and software developed for DNA microarrays. In practice, multiple antigens or reactive epitopes are printed onto an array surface in a predetermined configuration. Performing an assay using a patient serum sample or other biological fluids on this substrate allows for the simultaneous and rapid detection of multiple autoantibodies. A recent report of this technology concluded that the use of

autoantigen microarrays represents a powerful tool to study the specificity and pathogenesis of autoantibody responses (24).

Commercialization of this technology to the clinical diagnostic market shows promise. In the future, typical applications will provide an entire system that includes the relevant pre-coupled or spotted arrays, the equipment for sample handling and performance of the test, and software to analyze and report the results. The challenge is to produce consistent, repeatable, reliable and economical tests that rely on manufacturing arrays in a controlled environment. One of the keys to this technology will be the ability to use a single array for numerous tests. This means the stability of antigens after stripping and 're-charging' the array will be important factors.

Laser microbead array

The laser bead microarray platform is a variation of the array concept that has already entered the market. This technology is largely based on the Luminex 100 equipment (Luminex Corp., Austin, TX) that incorporates laser flow technology to analyze reactants in a microtiter format. The key component of this technology is microspheres that are available in up to 100 different laser-reactive colors (Figure 4). In practice, an antigen of interest is chemically coupled to a specific colored microsphere. A second or third antigen is coupled to a microsphere of a different color. After the coupling and stabilizing reactions, the antigen-coupled spheres can be combined into a single microtiter well to provide a single assay that has the ability to detect multiple antibodies in a single specimen. The test sample (serum or other biological fluid) and a fluorochrome-coupled secondary antibody are then added to the well. The sample is then analyzed using principles that are similar to flow cytometry with one laser identifying the specific antigen-coupled bead passing through the path and a second laser determining the presence and quantity of secondary antibody bound to the bead. The data is displayed in a number of formats and can be expressed as a quantitative analysis of multiple analytes and the relative amount of antibody bound to the antigen.

The advantages of this platform include the capacity to analyze a complex array of autoantibodies in a single sample with speed and precision. At least one kit for simultaneously detecting up to six autoantibodies relevant to systemic rheumatic diseases is currently available (ENA Profile 6: Inova Inc., San Diego, CA). Early studies of this kit showed a high level (>90%) of agreement with conventional techniques (unpublished data). Advantages of this technology includes small amounts (5 μ l) of serum required for the assay and test sera and secondary antibody are added as a single step with no washing of beads




Fig. 4: Laser bead antigen arrays are developed by chemically coupling the antigen of interest onto microbeads that have incorporated a laser reactive dye (panel a). In practice each antigen is coupled to a differently colored bead and the antigens on different colored beads can then be combined into a single microtiter well (panel b). The test serum and secondary antibody coupled to a fluorochrome are then added to the well and analysis is conducted with technology that is similar to flow cytometry. One laser determines the identity of the bead (color=antigen of interest) and another laser simultaneously scans the bead to determine the presence and amount of fluorochrome-labeled secondary antibody (panel c).

required. These factors combine to generate rapid test results since analysis of multiple antibodies in a single well typically takes less than two minutes. In addition, test reports can be automatically generated through Excel or other database management software.

Microfluidics

Microfluidics technology, also referred to as “lab on a chip”, is currently under development and evaluation (25;26) (27;28). This technology is adaptable to a number of different configurations and it involves the miniaturization and integration of liquid and biological fluid handling and analysis on microfabricated devices (29-31). These devices are manufactured by etching or molding interconnecting channels onto glass, quartz, silicon or other solid phase matrices. The equipment and software is designed to provide a hard-wired testing protocol. The design can include pumps, valves, extraction and separation modules, reaction chambers, and channels that permit rapid processing of test samples (Figure 5). Unlike conventional laboratory techniques that require human intervention at multiple steps to manipulate or evaluate samples, this technology has the potential to be virtually hands-free.




Fig. 5: A typical microfluidics, microarray, nanochip cartridge (permission to copy NanoChip™ Cartridge, Nanogen, Inc., San Diego CA). These devices can be adapted to conduct antigen-antibody analyses by placing antibody or serum in chamber #1 or in chamber #2. The microarray would include microspots of relevant antigens.

In principle, antigen, antibodies, buffers and analytes are moved, switched and combined under the influence of electrokinetic forces so that unique physicochemical properties can be detected when two proteins form an antigen-antibody complex. Future microfluidics platforms may include a module that will physically prevent blood cells and other particulate debris from entering the reaction chamber (32). In this way a small amount of whole blood (i.e. finger prick) can be utilized without the need for to process blood samples to obtain serum.

The advantage of microfluidics includes the combined potential of a large number of parallel channels, short distances, and high electrical fields that will increase throughput by several orders of magnitude. The integration of multiple analytes on a single chip and the relatively small amount of reagents and materials required for a single analysis holds promise for a very rapid and relatively inexpensive technology to detect autoantibodies.

One application of microfluidics is based on capillary electrophoresis (26;28). This technology will allow antigens and antibodies to be in an aqueous environment thus preserving protein structure and theoretically allowing for optimal antigen-antibody interactions *in vitro*. This platform is similar to other microfluidics platforms wherein the antigen and antibody 'streams' are brought together and mixed in a common microchannel and allowed to react for various times. The antigen-antibody conjugates are then separated or distinguished from unreacted proteins and detected on the basis of flow characteristics that are related to electrophoresis and electroosmosis when an external electric field is applied. This technology requires very small volumes (i.e. picoliters) and quantities (i.e. nanograms) of reactants for each assay (28). This is in contrast to the solid phase detection microarray systems where nanoliter spot sizes require high sample density. This platform has the flexibility to combine an assay with simple antigen-antibody binding event detection and measurement of antibody binding affinity and avidity. Perhaps most important to the clinical laboratory, the detection time for this technology is extremely rapid. For example, in a single assay the analysis is limited only by the transport of samples from the reservoirs, the maximum electric field that can be used, and the rate of reaction of antibody with antigen. In practice, this can be achieved in approximately 500 milliseconds.

Nanotechnology and nanoengineering

Nanotechnology is defined as the creation of functional materials, devices, and systems through the control of matter as a scale of 1 – 100 nanometers. In addition, this technology is able to exploit the novel properties of and phe-

nomena of antigen-antibody binding at the atomic level. This technology not only provides the potential of the ultimate in microfluidics diagnostics *ex vivo* but it also provides the opportunities to develop diagnostic tools that can be targeted to specific organs and to specific cells within organs. Clearly this is a major focus for the future of diagnostics and therapeutics alike.

Summary

Advances in technologies are rapidly changing the approach to diagnostic serology. The integration and adoption of these new technologies has promise of improving the sensitivity, specificity, speed and cost of autoantibody testing. However, these technologies will also produce new and complex data sets that may require revision of existing diagnostic and therapeutic paradigms. The widespread use of newer technologies requires dialogue (33) and the input of clinicians, engineers, basic scientists and the standardization of the assays based on highly characterized and standardized sera and reagents.

Abbreviations

ANA, antinuclear antibody; CIE, counterimmunoelectrophoresis; CENP, centromere protein; CF, complement fixation; ELISA, enzyme linked immunoassay; ENA, extractable nuclear antigens; HA, hemagglutination, IB, immunoblotting; ID, immunodiffusion; IP, immunoprecipitation; kDa, kiloDalton; PM, polymyositis; RA, rheumatoid arthritis, RIA, radioimmunoassay; SjS, Sjögren's syndrome; SLE, systemic lupus erythematosus; SS-A/Ro, Sjögren's syndrome antigen A; SSc, systemic sclerosis.

References

1. Chan EKL, Buyon JP. The SS-A/Ro antigen. In: Van Venrooij W, Maini RN (Eds.) Manual of Biological Markers of Disease (pp. 1-18). Dordrecht, The Netherlands: Kluwer Academic Publishers, 1994
2. Boire G, Craft J. Human Ro ribonucleoprotein particles: characterization of native structure and stable association with the La polypeptide. *J Clin Invest* 1990; 85: 1182-1190
3. Boire G, Lopez-Longo F-J, Lapointe S, Menard H-A. Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein. *Arthritis Rheum* 1991; 34: 722-729

4. Tan EM, Smolen J, McDougal JS, Butcher BT, Conn D, Dawkins R et al. A critical evaluation of enzyme immunoassays for the detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity and specificity. *Arthritis Rheum* 1999; 42: 455-464
5. Tan EM, Smolen JS, McDougal JS, Klippel JH, Fritzler MJ, Gordon TP et al. A critical evaluation of enzyme immunoassay kits for the detection of antinuclear antibodies of defined specificities. II. Potential for quantitation of antibody content. *J Rheumatol* 2002; 29: 68-74
6. Manoussakis MN, Kistis KG, Liu X, Aidinis V, Gualis A, Moutsopoulos HM. Detection of anti-Ro(SS-A) antibodies in autoimmune diseases: comparison of five methods. *Br J Rheumatol* 1993; 32: 449-455
7. Meilof JF, Bantjes I, de Jong J, Van Dam AP, Smeenk RJT. The detection of anti-Ro(SS-A) and anti-La(SS-B) antibodies. A comparison of counterimmunoelectrophoresis with immunoblot, ELISA, and RNA-precipitation assays. *J Immunol Meth* 1990; 133: 215-226
8. Hendrick JP, Wolin SL, Rinke J, Lerner MR, Steitz JA. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. *Mol Cell Biol* 1981; 1: 1138-1148
9. Harmon CE, Deng JS, Peebles CL, Tan EM. The importance of tissue substrate in the SS-A/Ro antigen-antibody system. *Arthritis Rheum* 1984; 27: 166-173
10. Fritzler MJ. Autoantibody testing: Procedures and significance in systemic rheumatic diseases. *Meth Achiev Exp Pathol* 1986; 12: 224-260
11. Thomsen DR, Stenberg RM, Goins WF, Stinski MF. Promoter-regulatory region of the major immediate early gene of human cytomegalovirus. *Proc Natl Acad Sci USA* 1984; 81: 659-663
12. Keech CL, McCluskey J, Gordon TP. Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. *Clin Immunol Immunopath* 1994; 73: 146-151
13. Fritzler MJ, Hanson C, Miller J, Eystathioy T. Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. *J Clin Lab Anal* 2002; 16: 103-108
14. Baier JE, Poehlau D. Is α -methyl-dopa-type autoimmune hemolytic anemia mediated by interferon-gamma. *Ann Hematol* 1994; 69: 249-251
15. Keech CL, Howarth S, Coates T, Rischmueller M, McCluskey J, Gordon TP. Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60 kDa Ro HEp-2 transfectants. *Pathology* 1996; 28: 54-57
16. Pollock W, Toh BH. Routine immunofluorescence detection of Ro/SS-A autoantibody using HEp-2 cells transfected with human 60 kDa Ro/SS-A. *J Clin Pathol* 1999; 52: 684-687
17. Bossuyt X, Meurs L, Mewis A, Marien G, Blanckaert N. Screening for autoantibodies to SS-A/Ro by indirect immunofluorescence using HEp-2000TM cells. *Ann Clin Biochem* 2000; 37: 216-219

18. Morozzi G, Bellisai F, Simpatico A, Pucci G, Bacarelli MR, Campanella V et al. Comparison of different methods for the detection of anti-Ro/SSA antibodies in connective tissue diseases. *Clin Exp Rheumatol* 2000; 18: 729-731
19. Peene I, Van Ael W, Vandenbossche M, Vervaeet T, Veys E, De Keyser F. Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. *Clin Rheumatol* 2000; 19: 291-295
20. Fritzler MJ, Wall W, Gohill J, Kinsella TD, Humbel R-L. The detection of autoantibodies on HEp-2 cells using an indirect immunoperoxidase kit (Colorzyme). *di* 1986; 4: 217-221
21. Meheus L, Van Venrooij WJ, Wiik A, Charles PJ, Tzioufas AG, Meyer O et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear antibodies in connective tissue disorders. *Clin Exp Rheumatol* 1999; 17: 205-214
22. van der Linden MW, Rudi GJ, Westendorp MZ, Meheus L, Huizinga TWJ. Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens. *J Rheumatol* 2001; 28: 284-287
23. Rutjes SA, Vree Egberts WT, Jongen PH, Pruijn G, Van Venrooij JV. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. *Clin Exp Immunol* 1997; 109: 32-40
24. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. *Nature Med* 2002; 8: 295-301
25. Robinson WH, Steinman L, Utz PJ. Proteomics technologies for the study of autoimmune disease. *Arthritis Rheum* 2002; 46: 885-893
26. Sanders GHW, Manz A. Chip-based microsystems for genomic and proteomic analysis. *Trends Analyt Chem* 2000; 19: 364-378
27. Kniss R. Revolution of the drug discovery process using laboratory-on-a-chip technology. *Amer Lab* 1998; 30: 40-42
28. Utz PJ. Microfluidics and proteomics. <http://www.stanford.edu/group/utzlab/proteomics.htm>, 2002
29. Polson NA, Hayes MA. Microfluidics: controlling fluids in small places. *Anal Chem* 2001; 73 (11): 312A -319A
30. Mitchell P. Microfluidics--downsizing large-scale biology. *Nat Biotechnol* 2001;19 (8): 717 -21
31. Davies MJ. Microfluidics venture. *Trends Biotechnol* 2001; 19 (9): 331-332
32. Nicholson P. Big things come in small packages. *Biotechnol Focus* 1999: 16-29
33. Utz PJ. 21st European workshop for rheumatology research, Vienna, Austria, 1-4 March 2001. *Arthritis Res* 2001; 3: 237-240

Systematic analyses of microbial antigens and infection induced autoimmunity

*P. Krebs¹, B. Ludewig¹, B. Metters¹, O. Türeci²,
R. M. Zinkernagel¹, H. Hengartner¹, U. Sahin²*

¹Institute of Experimental Immunology, Department of Pathology, University Hospital Zürich, Zürich, Switzerland; ²III. Medical Clinic, Johannes Gutenberg University Mainz, Mainz, Germany

A number of viral and bacterial infections are associated with antibody-mediated autoimmune diseases. Using the SEREX approach (SERological identification of Recombinantly EXpressed antigens), we systematically dissected the autoantibody repertoire of mice after infection with cytopathic or non-cytopathic viruses. cDNA expression libraries prepared from various organs 48-72h after infection were immunoscreened using sera harvested from virus-infected mice. Screening of more than $2,5 \times 10^6$ clones demonstrated that virus-induced autoimmune B cell responses are of broad specificity; e.g., antibody responses against more than 60 autoantigens were detected after Vaccinia virus (VV) infection. Interestingly, the vast majority of the identified autoantigens after VV infection, which include intracellular enzymes, transcription factors, cytoskeletal proteins and surface molecules, have been previously described as autoantigens in humans. Antibody titers against a number of autoantigens were comparable to anti-VV antibody responses. Comparison of serum reactivity against a selected panel of autoantigens after infection with VV, lymphocytic choriomeningitis virus or vesicular stomatitis virus showed that the different virus infections leave distinct pattern of autoreactivity in the infected host. These data indicate that virus infections are responsible for a significant fraction of the autoantibody repertoire and that individual viruses may trigger specific "autoantibody fingerprints".

Line-assay with recombinant antigens for diagnosis of systemic autoimmune rheumatic diseases

T. Kattenfeld¹, A. Kromminga², M. Motz¹

¹Mikrogen GmbH, Martinsried, Germany; ²Institute for Immunology, Clinical Pathology, Molecular Medicine (IPM), Hamburg, Germany

The goal of this project was to develop an easy-to-use test system with high sensitivity and specificity for detecting circulating autoantibodies in sera of patients with systemic autoimmune rheumatic diseases, like SLE, Sjögren's syndrome, scleroderma, myositis and others. Therefore we have cloned the cDNA of 13 antigens including RNP-70kD, RNP-A, RNP-C, SmB, SmD, SSA-60, SSA-52, SSB, ribosomal P0-protein, PCNA, CENP-B, DNA topoisomerase I (ScI70), and histidyl-tRNA synthetase (Jo1). The cDNAs were expressed heterologously in *E. coli* bacteria and SF21 insect cells, respectively, and were purified by successive chromatographic procedures. The recombinant proteins as well as native dsDNA and histones were brought on nitrocellulose membrane strips by dot-blot technique. Using this test format we analyzed 380 sera of patients with different types of connective tissue diseases, 50 sera of vasculitis patients, 20 sera of patients with rheumatoid arthritis, 50 with reactive arthritis, and 220 sera of normal subjects. We have found high agreement of our results with those obtained from other available test systems. In addition, this test format serves as a fast method to distinguish between autoimmune and other rheumatic diseases with similar symptoms. The high sensitivity and specificity of this assay and its easy interpretation as well as its simple laboratory procedure makes this assay to a promising tool in the differential diagnosis of autoimmune rheumatic diseases.

Three multiplexed tests for extractable nuclear antigens using the Luminex 100

*R. W. Burlingame¹, A. L. Piette¹, C. von Mühlen²,
K. M. Pollard³, W. L. Binder¹*

¹INOVA Diagnostics, Inc., San Diego, CA, USA; ²PUC School of Medicine, Porto Alegre, Brazil; ³The Scripps Research Institute, La Jolla, CA, USA

We developed convenient multiplexed immunoassays for the detection of autoantibodies to the extractable nuclear antigens Sm, RNP, SSA, SSB, Scl-70 and Jo-1. The results obtained with this new technology were compared to clinical diagnosis and the results found with standard ELISA methodology.

A no-wash multiplexed assay that detects autoantibodies to up to 6 antigens in a single well was developed. Each of the 6 antigens is coated on a unique bead. The appropriate beads are then mixed in a single well as either a 4-plex comprised of Sm, RNP, SSA and SSB, a 5-plex comprised of those 4 antigens plus Scl-70, or a 6-plex comprised of those 5 antigens plus Jo-1. These are called QUANTA Plex tests. Sera from normal blood donors, from patients with clinically defined rheumatic diseases, and from samples with high titers of specific antibodies were tested on all multiplex tests and the corresponding ELISAs.

Samples from 200 normal blood donors were tested, and for every antigen on both technologies at least 99% were negative. The cutoff between negative and positive on the QUANTA Plex tests ranged between 4 and 13 standard deviations above the average of this group. Over 250 samples from patients with systemic lupus erythematosus, scleroderma and Sjogren's syndrome were tested on the QUANTA Plex tests and ELISAs. Compared to ELISA, the relative sensitivity for each QUANTA Plex test was about 95%, and the relative specificity was 98% or higher. Thus, it is not surprising that the ELISA and QUANTA Plex tests had the same clinical sensitivity and specificity. Control sera with antibodies to known infectious disease organisms or irrelevant autoantigens showed the same sensitivity and specificity on the QUANTA

Plex tests and ELISAs. Adding beads with Scl-70 and Jo-1 antigens to the QUANTA Plex ENA Profile 4 did not change the reactivity of any sera to the original 4 antigens.

Conclusion: The 3 QUANTA Plex ENA Profile tests using the Luminex flow cytometer yield sensitivity and specificity nearly identical to ELISA. There are no measurable interactions among the different beads in the same well. Performing all assays for a given sera in only 1 well saves space and time.

The BIOONE® system: The new dosage of autoantibodies

*L. Voorn, P. Backelandt, A. Duyckaerts, L. Zecchinon,
T. Swiatkowski, A. Bosseloir*

*Zentech S.A., R&D department, Parc Scientifique du Sart-Tilman, Angleur,
Belgium*

The concentration of autoantibody in serum from autoimmune patients are determined with several methods existing and available in the market (ELISA with direct coating of autoantigen, Immunoblot, RIA, IFA). We have recently developed a new method, called BIOONE®, using one and only one microtiterplate coated with streptavidin for major autoimmune parameters.

The specific autoantibodies in diluted serum react with soluble biotinylated autoantigen during the first incubation time (30 min. at 37°C). In the same time, the complex formed react directly with the solid phase. After washing, a peroxidase conjugated antibody is added to the wells and incubated (60 min. at 37°C). A last washing step remove the unbound conjugate and specific autoantibodies are traced by incubation with substrate solution (15 min. at 37°C).

We evaluated the BIOONE® system for the diagnosis of AITD (autoimmune thyroid diseases) and ANCA (MPOAb, PR3Ab and mix). Intra-assay precision were found to be < 10% and inter-assay to be < 15%. The clinical results have been also compared with other commercial ELISA and/or IFA technics.

General conclusion, the BIOONE system:

- has a good correlation with the reference methods.
- individualizes the dosage. The autoantigen can be distributed anywhere into the microtiterplate; open to evolution of autoimmune diseases diagnostic (many tests with few patients).

- permits the analysis of aspecific binding with the solid phase (omission of autoantigen during the first incubation time). Aspecific binding against plastic of microtiterplate or streptavidin.
- keeps the native form of autoantigen. No modification of the 3D structure following direct adsorption.
- permits a complete access of autoantigen for autoantibodies.
- optimizes the concentration of autoantigen.

Automatized classification of HEp-2-cell based indirect immunofluorescence patterns by a novel computerized system

U. Sack¹, S. Knöchner¹, P. Perner², U. Pigla³, M. Kamprad¹

¹Institute of Clinical Immunology and Transfusion Medicine, University of Leipzig, Leipzig, Germany; ²Institute of Computer Vision and Applied Computer Sciences; ³Biotectid GmbH, Leipzig

In diagnosis of systemic autoimmune diseases, indirect immunofluorescence with HEp-2-cells presents the major screening method. This procedure allows to scan a broad range of autoantibodies and to classify them by distinct fluorescence patterns. The identification of the patterns is currently done manually by inspecting the slides with the help of a microscope. The major disadvantages of this method are the need for highly specialized technicians and a lack of automatized solutions. Furthermore, need for standardization and documentation is hampered by the common microscopic technique.

We have established a novel system for automatized classification of HEp-2 fluorescent patterns. Designed as an assisting system, representative patterns are acquired by an operator with a digital microscope camera and transferred to a personal computer. A software package was developed based on a novel image analysis and feature extraction algorithm. The generated data set was then subject to machine learning techniques to find out relevant features for a correct classification of autoantibodies. The learning algorithm selected from the data set the most promising features and constructed the structure of a classifier during the learning phase.

Our results show, that identification of positive fluorescence and discrimination between most important autoantibody entities can be performed by this system. The decision tree as generated in the learning phase can be integrated in the laboratory system. To enable the usage of such a system in routine diagnostics, accuracy of this system must be further improved. At the moment, more than 80 percent of samples can be classified in a correct way. Furthermore, overall speed of the system must be enhanced.

We conclude that the established system can be used as an automatic inspection module. The integrated software for machine learning allows to permanently improve reliability of classification as well as number of recognized autoantibody entities.

Simple and sensitive detection of serum autoantibodies to full-length bullous pemphigoid antigen 180¹

*E. Schmidt^{1,3}, A. Kromminga², D. Zillikens³,
U. Zimmermann¹*

¹Department of Biotechnology, Biocenter, University of Würzburg, Würzburg, Germany; ²Institute of Immunology, Clinical Pathology, and Molecular Medicine (IPM), Hamburg, Germany; ³Department of Dermatology, University of Würzburg, Würzburg, Germany

Introduction

Bullous pemphigoid (BP), the most common autoimmune bullous skin disorder (1,2), is characterized by tissue-bound and circulating autoantibodies to the hemidesmosomal proteins BP180 and BP230 (3,4). Whereas BP230 is localized intracellularly to the hemidesmosomal plaque, BP180 is a type II transmembrane glycoprotein with a C-terminal ectodomain that contains 15 interrupted collagenous domains and spans the lamina lucida of the dermal-epidermal junction (DEJ; reviewed in 5). BP180 is essential for the integrity of the DEJ since mutations in the BP180 gene result in an inherited blistering skin disorder that was characterized by loss of adhesion within the DEJ (reviewed in 6).

The majority of BP sera reveals reactivity with the 16th non-collagenous (NC) domain directly adjacent to the transmembrane portion (NC16A; 7-9). Reactivity of BP sera with other intra- and extracellular sites located on BP180 has also been reported (10-12). The pathogenic relevance of anti-BP180 antibodies has previously been demonstrated by the passive transfer of rabbit anti-BP180 antibodies into neonatal mice (13). In addition, in BP patients, levels of

¹ Presented in detail in Ref. 23.

circulating antibodies to BP180 NC16A have been shown to parallel disease activity (14).

BP is usually diagnosed by the use of several assays, including (1) direct immunofluorescence (IF) microscopy of a perilesional skin biopsy, (2) histopathology of a lesional biopsy, and (3) indirect IF microscopy of patient sera on 1M NaCl-split human skin, i.e. an assay which can distinguish between epidermal and dermal binding of autoantibodies (15; reviewed in 16). These assays, however, have several drawbacks: Both IF microscopy and histopathology require skin biopsies and indirect IF on salt-split skin does not distinguish between different specificities of autoantibodies directed to different components of the DEJ and strongly depends on the quality of human split-skin that may vary considerably. More recently, recombinant fragments of BP180 were employed for the detection of serum autoantibodies in BP by Western blotting (WB) and enzyme linked immunosorbent assay (ELISA; 7-12,17-19). The disadvantage of these assays is that recombinant fragments were frequently generated in prokaryotic cells, thus conformation-dependent epitopes may not be expressed. In addition, they do not encompass the full-length (FL) BP180 molecule.

In the present study, we expressed FL-BP180 as a type II transmembrane protein by the use of an eukaryotic expression system and, subsequently, developed a simple and highly sensitive and specific assay for the detection of circulating antibodies to BP180 that may be used in any routine IF laboratory.

Results

Full-Length (FL) BP180 was expressed as Type II Transmembrane Protein in Sf21 Insect Cells. Sf21 insect cells were infected by recombinant baculovirus encoding FL-BP180 (MOI=4.0; 20), fixed with acetone, and labeled with various mouse mAb to BP180 (see schematic diagram in Fig. 1; 21, 22). By confocal laser scanning microscopy FL-BP180 was shown to be expressed uniformly within the cell membrane of Sf21 insect cells (data not shown; 23). In order to demonstrate that FL-BP180 is expressed as type II transmembrane protein (like in the human keratinocyte), FL-BP180 expressing Sf21 insect cells and cells infected with a negative control construct were incubated with mAbs to BP180, respectively. Analysis by flow cytometry revealed that mAbs against the extracellular domain of BP180 were bound, but not the mAb against the intracellular domain unless the cell membrane of the FL-BP180-expressing insect cells had been permeabilized prior to incubation with mAb directed to the intracellular domain (data not shown; 23).




Fig. 1: Schematic diagram of recombinant and cell-derived forms of human BP180. The N-terminal cytoplasmic domain of BP180 (left side) and the C-terminal ectodomain (right side) consisting of 15 interrupted collagen domains (gray boxes) are shown. Amino acid numbers are depicted next to the proteins. The epitopes recognized by the mouse monoclonal antibodies (mAb) to human BP180 used in this study are indicated at the top of the panel. TM, transmembrane portion of BP180.

Detection limits of the Sf21-based immunofluorescence assay

In order to quantitatively determine the sensitivity of the IF assay using FL-BP180-expressing Sf21 insect cells, binding of the mouse mAbs 233, HD18, and 1A8c was studied at serial dilutions of 1:5 to 1:20,480 by indirect IF microscopy (23). While no staining was seen with the control cells infected with the negative control construct (encoding the hexa-histidine tag; data not shown), the mAbs labeled the FL-BP180-expressing Sf21 insect cells (Fig. 2). The sensitivity of the Sf21-based IF assay was compared with (1) indirect IF microscopy on salt-split skin, (2) WB of FL-BP180 generated in Sf21 insect cells, and (3) WB of recombinant BP180 NC16A (Table 1; 23). It is evident that the eukaryotic IF assay was more sensitive than the conventional assays. Based on the IgG concentration in mAb preparations and the data in Table 1, the detection limit of the eukaryotic IF assay was calculated to be 72 ng/ml (mAb233), 17 ng/ml (mAbHD18), and 16 ng/ml (mAb1A8c).

Detection of serum antibodies to BP180 in patients with bullous pemphigoid

To further characterize the sensitivity and specificity of the Sf21-based IF assay 65 sera of BP patients with circulating antibodies to the DEJ as detected by indirect IF microscopy on salt-split human skin were examined. As shown by screening experiments, nonspecific staining occurred in about a third of human sera derived from both patients and healthy controls. Nonspecific IF




Fig. 2: Full-length BP180 expressed in Sf21 insect cells is recognized by mouse monoclonal antibodies directed against both intra- and extracellular epitopes on human BP180. When Sf21 insect cells were infected with baculovirus encoding full-length BP180 at a multiplicity of infection of 4.0, about 30% cells were strongly stained after fixation with acetone and incubation with various mouse monoclonal antibodies (mAb) to human BP180 (for details see Fig. 1). Non- or weakly-stained cells served as internal negative control. No staining was seen with mAb1E5 directed against human BP230.

reactivity varied considerably between the different sera and was present in both FL-BP180-expressing Sf21 insect cells and cells infected with the control construct. However, when the sera were pre-incubated with non-infected Sf21 insect cells, the unspecific background staining could greatly be reduced (Fig. 3; 23). After pre-adsorption 58 of 65 BP sera (89%) were reactive. In contrast, no reactivity was observed with sera from patients with pemphigus vulgaris (n = 15), pemphigus foliaceus (n = 5), epidermolysis bullosa acquisita (n = 5), atopic dermatitis (n = 7), contact dermatitis (n = 3), systemic lupus erythematosus (n = 5) as well as with normal human sera (n = 30). Results of BP sera obtained by the Sf21-based IF assay were then compared with WB of (1) FL-BP180, (2) a 55 kD C-terminal fragment of BP230, and (3) the cell-derived

Tab. 1: Sensitivity of immunofluorescence (IF) microscopy of full-length (FL)-BP180-expressing Sf21 insect cells compared with the sensitivity of current assays using serial dilutions of mouse monoclonal antibodies directed to various intra- and extracellular epitopes on BP180

Designation	Immunofluorescence		Immunoblotting	
	FL-BP180 ¹	Salt-split Skin	FL-BP180	BP180 NC16A
233	1,280	1,280	20	na
HD18	640	20	5	640
1A8c	2,560	640	10,240	na

¹expressed in Sf21 insect cells fixed with acetone; na, not applicable; NC16A, extracellular portion of the 16th non-collagenous domain of BP180




Fig. 3: Preadsorption of BP sera with non-infected Sf21 insect cells reduced unspecific background immunofluorescence (IF) staining of negative control construct-infected Sf21 insect cells. Sf21 insect cells were infected with baculovirus encoding full-length BP180 (FL-BP180) or a hexa-histidine peptide (negative control construct). Without preadsorption, the bullous pemphigoid (BP) serum strongly labeled FL-BP180-expressing Sf21 insect cells. However, unspecific staining is seen in cells infected with the negative control construct. After preadsorption of the BP serum with non-infected Sf21 insect cells, the serum still labeled FL-BP180-expressing insect cells but nonspecific staining of negative control construct-infected cells was greatly reduced.

Tab. 2: Detection of antibodies to BP180 in 65 bullous pemphigoid sera that contained antibodies against components of the dermal-epidermal junction determined by the eukaryotic immunofluorescence assay and conventional assays

FL-BP180		NC16A ¹	LAD-1 ¹	BP230 55 kD ¹
Sf21 Insect Cells ²	Immunoblot			
58/65	39/65	49/65	38/65	38/65
89%	60%	75%	58%	58%

¹analyzed by immunoblotting; ²detected by indirect immunofluorescence microscopy; FL-BP180, full-length BP180; NC16A, extracellular portion of the 16th non-collagenous domain of BP180; LAD-1, linear IgA disease antigen (cell-derived ectodomain of BP180); BP230-55 kD, 479 amino acid C-terminal stretch of BP230

soluble ectodomain of BP180 (LAD-1; Table 2; 23). Comparison of the data shows that indirect IF microscopy of FL-BP180-expressing Sf21 insect cells appears to be the most sensitive tool for the detection of circulating antibodies against BP180.

Reactivity of stored FL-BP180-expressing Sf21 insect cells

FL-BP180-expressing Sf21 insect cells and cells infected with the negative control construct were fixed with acetone and stored at 4-8°C or -20°C for 3 months. After thawing, cells were labeled with mouse mAbs 233, HD18, and 1A8c to BP180 (for details see Fig. 1) at dilutions of 1:320 and 1:640 (23). Reactivity was compared with cells that were prepared on the same day and fixed with acetone and scored from “+ + +” for bright staining to “+/-” for faint staining (Table 3; 23). When cells were stored at 4-8°C, no or only weak staining was observed; in contrast, reactivity to BP180 was conserved in FL-BP180-expressing cells when stored at -20°C. However, the reactivity was about one titre step lower compared with freshly prepared cells (Table 3).

Discussion

The data presented here show that the indirect IF microscopy of full-length BP180-expressing Sf21 insect cells is more sensitive for anti-BP180 antibodies than conventional assays, such as indirect IF microscopy on human salt-split

Tab. 3: BP180 expression is largely conserved upon storage of full-length BP180-expressing Sf21 insect cells at -20°C for 3 months

Designation ¹	Fresh ²	-20°C ³	4-8°C ³
mAb233	+++ ⁴	++	+/-
mAbHD18	+	+/-	-
mAb1A8c	+++	++	-

¹mouse monoclonal antibodies (mAb) 233, HD18, and 1A8c directed against various epitopes on human BP180 (for details see Fig. 1) were tested at dilutions of 1:320 and 1:640; ²prepared, fixed with acetone, and stained on the same day; ³stored for 3 months after fixation with acetone; ⁴immunofluorescence reactivity was scored from “+++” for bright to “+/-” for faint staining. When no staining was seen, the score was “-”.

skin, Western blotting of recombinant and cell-derived fragments of BP180, as well as Western blotting of FL-BP180 produced in Sf21 insect cells. This conclusion can be drawn from the low detection limit of the eukaryotic IF assay as determined by serial dilutions of BP180-specific mouse monoclonal antibodies and from the reactivity with a large panel of BP and negative control sera. About 90% of BP sera were found to be positive when unspecific background reactivity had been removed by pre-incubation of the sera with non-infected Sf21 insect cells. Background reactivity, detected in about one third of human sera (both patients and healthy volunteers), could be greatly reduced by (1) using a MOI of 4.0, (2) preadsorption of sera with non-infected Sf21 insect cells, and (3) controlling the preadsorption procedure by incubation of sera with control construct-infected Sf21 insect cells.

In contrast to the Sf21-based IF assay, in the case of Western blotting of recombinant BP180 NC16A and keratinocyte-derived LAD-1, only 75% and 60% of BP sera, respectively, were reactive. Similar reactivity for BP180 NC16A and LAD-1 in BP sera was reported by other authors (7, 9, 18, 19, 20, 24). Hata et al., using the recombinant ectodomain of BP180, found reactivity in about 85% of BP sera (25). With the same technique, 92% of BP sera were reported positive by Haase et al. (26). However, the protein was extracted under strongly denaturing conditions; thus it is unlikely that the physiological conformation of human BP180 was maintained. In addition, only sera of patients with generalized BP were tested (26). Furthermore, it is clear that the BP180 ectodomain can not cover the entire spectrum of anti-BP180 antibodies present in these patients since reactivity with the intracellular domain of BP180 was demonstrated in about a third of BP patients (12,20).

For routine use of the Sf21-based eukaryotic assay in laboratories without access to molecular biological technology it is interesting to note that in principle, FL-BP180 expression can be conserved (at least to a large extent) when

infected Sf21 insect cells were fixed with acetone and stored at -20°C. Further improvement of the storage conditions is certainly required and should be addressed in the nearest future.

Acknowledgments

We are grateful to Ulrich Leinfelder and Saskia Mimietz, Würzburg, Germany, for help with the flow cytometry analysis and confocal laser scanning microscopy, respectively. We thank Dr. Katshushi Owaribe, Nagoya, Japan for providing us with monoclonal antibodies 233 and 1A8c to BP180 and 1E5 to BP230. We also thank Dr. George J. Giudice, Milwaukee, USA that kindly provided us with rabbit antibody 136 to GST-BP180 4575.

References

1. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. *Arch Dermatol* 1995; 131: 48-52
2. Zillikens D, Wever S, Roth A, Hashimoto T, Bröcker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. *Arch Dermatol* 1995; 131: 957-958
3. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. *Cell* 1981; 24: 897-903
4. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. *J Immunol* 1986; 136: 1231-1235
5. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. *Arch Dermatol Res* 1999; 291: 187-194
6. Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. *J Invest Dermatol* 1999; 112: 411-418
7. Matsumura K, Amagai M, Nishikawa T, Hashimoto. The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen. *Arch Dermatol Res* 1996; 288: 507-509
8. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. *J Invest Dermatol* 1997; 109: 573-579
9. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, Hoffmann RG, Diaz LA, Giudice GJ. A highly sensitive enzyme-linked immunosorbent assay for the

- detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. *J Invest Dermatol* 1997; 109: 679-683
10. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. *J Immunol* 1993; 151: 5742-5750
 11. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, Zane JJ. Bullous pemphigoid sera that contain antibodies to BPAG2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. *J Invest Dermatol* 1999; 112: 148-152
 12. Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat JH, Borradori L. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. *J Invest Dermatol* 1999; 112: 141-147
 13. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. *J Clin Invest* 1993; 92: 2480-2488
 14. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. *Arch Dermatol* 2000; 136: 174-178
 15. Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. *Br J Dermatol* 1988; 118: 31-40
 16. Schmidt ES, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. *Adv Dermatol* 2000; 16: 113-57
 17. Balding SD, Prost C, Diaz LA, Bernard P, Bedane C, Aberdam D, Giudice GJ. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. *J Invest Dermatol* 1996; 106: 141-146
 18. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. *Br J Dermatol* 1998; 139: 365-370
 19. Husz S, Kiss M, Molnar K, Marczinovits I, Molnar J, Toth GK, Dobozy A. Development of a system for detection of circulating antibodies against hemidesmosomal proteins in patients with bullous pemphigoid. *Arch Dermatol Res* 2000; 292: 217-224
 20. Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E, Bröcker EB, Zillikens D. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. *J Autoimmun* 2000; 15: 293-300
 21. Hirako Y, Usukura J, Uematsu J, Hashimoto T, Kitajima Y, Owaribe K. Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. *J Biol Chem* 1998; 273: 9711-9717
 22. Pohl-Gubo G, Lazarova Z, Giudice GJ, Liebert M, Grassegger A, Hintner H, Yancey KB. Diminished expression of the extracellular domain of bullous pemphigoid antigen 2 (BPAG2) in the epidermal basement membrane of patients with

- generalized atrophic benign epidermolysis bullosa. *Exp Dermatol* 1995; 4: 199-206
23. Schmidt E, Kromminga A, Mimietz S, Leinfelder U, Sitaru C, Bröcker EB, Zillikens D, Zimmermann U. A Highly Sensitive and Simple Assay for the Detection of Circulating Autoantibodies against Full-Length Bullous Pemphigoid Antigen 180. *J Autoimmun* 2002; 18: 299-309
 24. Schumann H, Baetge J, Tasanen K, Wojnarowska F, Schäcke H, Zillikens D, Bruckner-Tuderman L. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. *Am J Pathol* 2000; 156: 685-695
 25. Hata Y, Fujii Y, Tsunoda K, Amagai M. Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression. *Dermatol Sci* 2000; 23: 183-190
 26. Haase C, Büdinger L, Borradori L, Yee C, Merk HF, Yancey K, Hertl M. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. *J Invest Dermatol* 1998; 110: 282-286

Rapid flow cytometric differentiation of anti-platelet antibodies with microspheres

M. Woetzel, S. Schroeder, U. Sack, F. Emmrich

*Institute of Clinical Immunology and Transfusion Medicine,
University of Leipzig, Germany*

Background

Allo- and autoantibodies against membrane structures of human platelets are involved in various types of immune thrombocytopenic disorders and can cause even life threatening bleeding. During the last decades a great variety of tests has been published with varying specificity. Most of these tests detect platelet-associated Ig (i.e. the presence of Ig on or within the platelet) without platelet-specific antibodies, but they cannot discriminate between specifically bound Ig and merely adsorbed immune complexes without a pathophysiological role (1,2). Substantial improvement resulted from the development of the widely accepted MAIPA (monoclonal antibody immobilization of platelet antigens) test (3). This test detects glycoprotein specific Ig selectively and is not hampered by immune complexes. However, MAIPA is time consuming and requires about $4\text{-}6 \times 10^7$ platelets, which is a serious limitation for patients with very low platelet counts and for little children with small blood volumes. The goal of this study was to overcome some of the limitations of the MAIPA test by utilizing the advantages of flow cytometry.

Material and methods

Preparation of microspheres

Goat anti-mouse Ig labelled magnetic microspheres (Dynal A.S, Oslo, Norway), goat anti-mouse IgG labelled polymeric beads (Bangs Labs., Inc., Fishers, IN, USA) and QuantumPlex™ Beads, consisting of dyed polymeric beads designed for multiplexed assays and labelled with goat anti-mouse Ig (Bangs Labs.), were used for these assays. Beads were washed twice with phosphate buffered saline (PBS) containing 0.1% sodium azide and 1% bovine serum albumin (BSA). They were subsequently incubated with monoclonal mouse anti-human antibodies anti-CD41 (Dianova, Hamburg) or anti-CD49b (clone Gi9) or anti- β_2 microglobulin (both from Coulter-Immunotech, Marseille, France) and stored over night at 4°C and also up to several months without loss of activity.

Preparation of platelets

Platelets were prepared from platelet rich plasma of well typed blood donors by three washings with PBS/BSA (1500g / 4°C). Platelets were incubated for 1 hour at room temperature or over night at 4°C with human platelet specific antisera (anti-HPA-1a, anti-HPA-5b), with HLA-antisera (anti-Bw4 and anti-Bw6, Biotest, Dreieich, Germany) or with human AB serum as negative control.

Detection of auto-/alloantibodies

After incubation these platelets were washed and treated as follows. Platelets with bound antisera of patients were solubilized with 0.5% Triton X-100. Simultaneously, Dynal beads with mouse anti-human antibodies were added to these lysed platelets in order to bind to their corresponding ligands, i.e. the bimolecular complexes. This incubation took 30 minutes at 4°C on a rotating shaker. After immobilization of membrane molecules, magnetic microspheres were washed twice on a magnet particle concentrator (MPC) from Dynal with PBS/BSA supplemented with 0.5mM CaCl₂ and incubated with biotinylated goat anti-human IgG (H + L), F(ab')₂ fragment (Jackson, ImmunoResearch Laboratories, West Grove, PA, USA) for 30 minutes at 4°C on a rotating device in order to label the bound allo-/autoantibody. Beads were washed twice on a MPC and stained with Extravidin® R-Phycoerythrin conjugate (Sigma). After a

final washing, beads were resuspended in PBS and run on a flow cytometer. Most of the following results from different experiments are reported as multiples of mean fluorescence intensity of AB serum ('relative MFI').

Results

Fig. 1 shows typical examples of intact platelets, labelled with HLA-alloantibodies or AB serum (negative control) and anti-human IgG R-PE, and of microspheres with HLA-molecules from lysed platelets and anti-human IgG R-PE. Intact platelets exhibit a very broad standard deviation with a mean




Fig. 1: Histograms of intact platelets loaded with alloantibodies and of HLA molecules of the same platelets after lysis and immobilization on Dynal beads.

Histograms from negative controls (AB serum) are presented by dashed lines.

value only slightly increased compared to the negative control. On the other hand, signals from lysed platelets are well separated.

How many platelets are necessary for one test?

Incubation of a constant amount of beads with increasing numbers of lysed platelets results in a linear increase of fluorescence signals (fig. 2), positive signals are obtained with less than 10^6 platelets if working with Dynal beads.

Titration of antiserum

Preincubation of constant numbers of platelets with increasing amounts of antiserum enhances signal strength (fig. 3). To compare the efficiency of Dynal beads with Bangs unstained beads and with QuantumPlex™ beads, several tests have been performed in one vial at the same time (multiplexed setting). Dynal beads give the strongest signals even with platelet antigens of low density (fig. 4).




Fig. 2: How many platelets per test are necessary? Platelets preincubated with anti-HLA sera have been titrated down to 1×10^5 /test before solubilization. If working with Dynal beads this is the minimal necessary amount of cells.




Fig. 3: Titration of antiserum. 2×10^6 platelets were preincubated with increasing amounts of antiserum, solubilized and bound to beads. Differences between both types of beads are significant ($p = 0,043$).




Fig. 4: Dynal beads produced the strongest signals in multiplexed experiments (mean of 6 experiments). Signals of Dynal and Bangs beads are significantly stronger at 5μl of antiserum than signals of QuantumPlex™ beads.

Is multiplexed analysis a way to improve the test?

QuantumPlex™ beads offer the advantage of simultaneously testing several platelet antigens in a few microliters of patients serum, yielding, however, smaller signals than Dynal beads. Fig. 5 gives an example of multiplexed testing with QuantumPlex™ beads. Platelets incubated with a mixture of various antisera were washed and lysed. Five batches of presensitized beads specific for different platelet antigens were mixed in one vial and added to the lysed platelets. If platelet antigens carry autoantibodies, then the complex of beads, membrane molecules and autoantibodies will be positively stained with reporter antibody labelled with Phycoerythrin. As discussed above, fig. 4 shows another example of multiplexed testing.

What about specificity and cross reactivity?

To check the specificity and to exclude any cross reactivity of this assay, well characterized platelets were incubated with known single or mixed antisera and lysed. The glycoproteins gpl_a/II_a were immobilized on QuantumPlex™




Fig. 5: Example of a multiplexed assay. Platelets were loaded with a mix of different antisera, solubilized and incubated with QuantumPlex™ beads.




Fig. 6: Cross reactivity has not been observed. Platelets of different donors were incubated with different antisera and lysed. The glycoproteins gplIIa were immobilized on QuantumPlex™ beads presensitized with anti-CD49b. Only samples with mixed antisera and with anti-HPA-5b give positive signals. Positive and negative signals are well separated.

beads which had been presensitized with anti-CD49b. As illustrated in fig. 6, positive and negative results are as expected and no cross reactivity has been observed. Specificity without cross reactivity was also obtained with beads presensitized with anti-CD41 (data not shown).

Discussion

The clinical importance of platelet specific allo- and autoantibodies, responsible for severe immune thrombocytopenias, requires a reliable and specific assay. Many published assays are not able to distinguish between specifically bound immunoglobulins and coating of membrane associated immune complexes on the surface of intact platelets, which why they can only be used as screening tests. Flow cytometry based tests on intact platelets have been pub-

lished, which quantify the amount of platelet associated Ig. They work fast and with as few as 10^5 to 10^6 platelets, but they are only of limited value (1,2). Further experiments with normal platelets, loaded over night with a mixture of anti-Bw4 and anti-Bw6 or with AB serum (data not shown), resulted in moderate, small or no differences between the mean values of specifically loaded platelets and negative controls and in very broad standard deviations of fluorescence signals (paper in preparation). These ambiguous and misleading results caused us to stop such experiments. On the other hand, signals from all of these specifically loaded platelets were unequivocally positive after solubilization with a very small standard deviation, as illustrated in fig. 1.

To date, the MAIPA test is well accepted as a routine method for detection of platelet specific antibodies. A three-molecular complex is immobilized and stained for quantitative determination with all other human immunoglobulines interfering with the test being washed out. However this test has some limitations, since it requires about $4-6 \times 10^7$ platelets, and hands-on time is about one day.

We have combined lysis of platelets and immobilization of membrane molecules on the bead surface without a need for centrifugation. Obviously, Dynal beads have a low tendency for nonspecific binding, which does not increase during this incubation.

Experiments have been performed to study some important test variables. Using Dynal beads, the minimal amount of platelets required was found to be about 10^5 to 10^6 platelets per test. Increasing numbers of specifically loaded platelets produced a linear increase of fluorescence signals. (Bangs and QuantumPlex™ beads are slightly different, paper in preparation.) If platelets were incubated before solubilization with increasing amounts of antibody, relative MFI increased logarithmically with Dynal beads being superior to Bangs beads. Similar experiments with QuantumPlex™ beads and a different antiserum confirm these results and show that QuantumPlex™ beads yield the lowest signals. Additionally, these tests are examples of multiplexed testing, since three beads have been pooled, incubated, afterwards stained in one vial and run simultaneously on a flow cytometer. Multiplexing is possible with beads of different size or if they are prestained with different amounts of a fluorescence dye by the manufacturer, as done with Quantum-Plex™ beads (see fig. 5).

An important question to be addressed is the avoidance of any cross reactivity. Different well characterized antisera have been pooled and incubated with different well typed test platelets, yielding results according to expectation, as shown in fig. 6. Thus, this test system produces reliable and specific data without signs of cross reactivity.

Conclusion

The important features of this method are

- the small amount of platelets and reagents needed,
- reduction of hands-on time (the total test takes about 3-4 hours),
- signal amplification using the biotin-Extravidin® binding and R-Phycoerythrin as a very strong dye,
- reading the samples by flow cytometry,
- fast and effective washing procedures using magnetic beads,
- multiplexing capabilities,
- very few problems with nonspecific binding and
- multiple choices for the use of optimized surfaces (if compared with multiwell plates as used for MAIPA).

The most useful type of beads for this purpose would be magnetic beads which are prestained with a fluorescence dye of different strength to perform multiplexing, with high specific antibody binding capacity and low tendency to nonspecific binding of human proteins. However, such beads are not yet commercially available.

Acknowledgement

We would like to thank Prof. V. Kiefel for his generous support of this work with antisera against HPA-1a and HPA-5b.

References

1. Legler TJ, Humpe A, Leib U, Riggert J, Köhler M. Flow-cytometric analysis of platelet reactive allo- and autoantibodies. *J Lab Med* 1997; 21: 676-680
2. Janisiw M, Eichelberger B, Koren D, Panzer S. Screening for platelet autoantibodies by flow cytometry and their evaluation by the MAIPA technique. *Wien Klin Wochenschr* 1998; 110 (15): 531-4
3. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. *Blood* 1987; 70: 1722-1726